Etienne Giroux‐Leprieur

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M. Duruisseaux, Anna Martínez‐Cardús, María Eréndira Calleja-Cervantes et al. · The Lancet Respiratory Medicine · 2018 · 214 citations · Full text

Anti-pd-1 Treatment, Medicine, Retrospective Analysis +10

Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab

Adrien Costantini, Catherine Julié, Coraline Duménil et al. · OncoImmunology · 2018 · 172 citations · Full text

Immunology, Immunoediting, Pathology +19

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 163 citations · Full text

Solid Cancer Patients, Cancer Epidemiology, Disease Risk Assessment +12

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma

Charlotte Domblides, Karen Leroy, I. Monnet et al. · Journal of Thoracic Oncology · 2020 · 133 citations · Full text

Medicine, Immune Checkpoint Inhibitors, Immunology +4

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

Manuela Tiako Meyo, Anne Jouinot, Etienne Giroux‐Leprieur et al. · Cancers · 2020 · 110 citations · Full text